The Celcuity management team will host a webcast/conference call on Monday, July 28, 2025 at 8:00 a.m. ET to discuss the topline results from the Phase 3 VIKTORIA-1 trial. Those who would like to ...

CEPI and POP BIO are committed to enabling equitable access to the outputs of their partnership, in line with CEPI’s ...

Dr. Shaltiel will present the Company’s exosome-based regenerative therapy platform at the Falling Walls Science Summit, taking place in Berlin, Germany from November 6-9, 2025. The winner, selected ...

Inidascamine was well-tolerated, with a favorable safety profile consistent with previous studies. Importantly, no evidence of sedation, weight gain, or extrapyramidal symptoms was observed, which are ...

With a 5.0-star rating on Google based on over 250 reviews, Movement Room is frequently recommended as one of the top choices ...

PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel ...

The Company intends to use the net proceeds from the Offering to pay $1,500,000 for marketing and advertising services to be provided by IR Agency LLC, $1,000,000 to fund the initial milestone payment ...

Phase 2b clinical trial of non-depleting anti-OX40 monoclonal antibody, IMG-007, in patients with moderate-to-severe atopic dermatitis Phase 2b topline readout for IMG-007 in atopic dermatitis ...

Abstracts will be published online via the ESMO website at 00:05 CEST on October 13 th 2025 (6:05 pm ET on October 12 th ). Following the presentations, copies of the presentations will be posted on ...

EMA’s CHMP issued an opinion not to recommend Elevidys™ (delandistrogene moxeparvovec) for the treatment of ambulatory individuals with Duchenne muscular dystrophy (DMD) Roche will continue its ...

The Houston Business Journal's Most Admired CEO Awards recognize chief executive officers who exemplify exceptional leadership, vision and values while guiding Houston's most successful and impactful ...

The transaction is expected to close on or about July 28, 2025, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering to fund ...